Deucrictibant
Prophylactic & On-demand treatment of Acquired Angioedema due to C1-INH deficiency (AAE-C1INH)
Key Facts
About Pharvaris
Pharvaris is a clinical-stage biotech focused on transforming the treatment landscape for hereditary angioedema (HAE) and other bradykinin-mediated conditions by developing oral alternatives to current injectable therapies. The company's lead asset, deucrictibant, is a potent, oral small-molecule B2 receptor antagonist being evaluated in two pivotal Phase 3 trials (RAPIDe-3 for on-demand and CHAPTER-3 for prophylaxis) and has shown promising efficacy and safety in Phase 2 studies. With a seasoned leadership team and a clear mission to provide patient choice through convenient, effective oral treatments, Pharvaris is positioned to address significant unmet needs in the rare disease market.
View full company profile